Learn About Acquired Agranulocytosis

What is the definition of Acquired Agranulocytosis?
Acquired agranulocytosis is a rare disorder characterized by a severe decrease in white blood cells (granulocytes) and is usually caused by drugs used to treat cancer, such as chemotherapy, and antipsychotic medications, such as clozapine, which interfere with the production of granulocytes in the bone marrow. The decrease in granulocytes makes individuals with acquired agranulocytosis more susceptible to bacteria infections from bacteria that would otherwise not be considered harmful in a healthy individual.
Save information for later
Sign Up
What are the symptoms of Acquired Agranulocytosis?
Early symptoms of acquired agranulocytosis are usually a bacterial infection that may include weakness, extreme fatigue, fever, chills, and infected ulcerations in the mucous membranes of the mouth, throat, and intestinal tract, along with difficulty swallowing (dysphagia) and irritation, pain, and swelling due to the ulcers. As the reduction in granulocytes (granulocytopenia) continues, patients with acquired agranulocytosis may develop an enlarged spleen (splenomegaly) and neutropenia (decreased blood neutrophils). In addition to the early symptoms, individuals with chronic acquired agranulocytosis may experience the development of canker sores in the mouth and gingivitis (inflammation of the gums) that regularly recurs.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Acquired Agranulocytosis?
The standard treatment for acquired agranulocytosis is the drug, filgrastim (Neupogen), in addition to identifying and discontinuing other drugs that may be causing the disorder. Some patients with acquired agranulocytosis may require treatment with antibiotics or corticosteroid therapy for associated bacterial infections. Immunocompromised patients with acquire agranulocytosis may require gamma globulin infusions. The associated mouth and throat ulcers can be treated with saline or hydrogen peroxide gargles, anesthetic lozenges, and antifungal mouthwashes containing the drug, nystatin, for oral fungal infections, such as thrush or Candida albicans (yeast infection). A liquid diet may be necessary until the ulcers heal. Acquired agranulocytosis will usually resolve once the granulocyte levels return to normal.
Who are the top Acquired Agranulocytosis Local Doctors?
GL
Gary H. Lyman
Dr. Gary H. Lyman
Oncology | Hematology Oncology
Elite
Highly rated in
12
conditions
Oncology
Hematology Oncology

SCCA Outpatient Clinic At South Lake Union

825 Eastlake Ave E 
Seattle, WA 98109

Gary Lyman is an Oncologist and a Hematologist Oncology doctor in Seattle, Washington. Dr. Lyman has been practicing medicine for over 50 years and is rated as an Elite doctor by MediFind in the treatment of Acquired Agranulocytosis. He is also highly rated in 12 other conditions, according to our data. His top areas of expertise are Febrile Neutropenia, Agranulocytosis, Venous Thromboembolism, and Acquired Agranulocytosis. He is licensed to treat patients in Washington. Dr. Lyman is currently accepting new patients.

View Profile
MA
Matti S. Aapro
Matti S. Aapro
Elite
Highly rated in
9
conditions

Clinique De Genolier

Oncology Department, Genolier Cancer Center 
Genolier, VD, CH 

Matti Aapro is in Genolier, Switzerland. Aapro is rated as an Elite expert by MediFind in the treatment of Acquired Agranulocytosis. They are also highly rated in 9 other conditions, according to our data. Their top areas of expertise are Febrile Neutropenia, Acquired Agranulocytosis, Agranulocytosis, and Breast Cancer.

View Profile
 
 
 
 
Learn about our expert tiers
Learn more
SA
Shin Y. Ahn
Distinguished
Highly rated in
9
conditions

University Of Ulsan

Department Of Internal Medicine, Kyunghee University 
Seoul, KR 

Shin Ahn is in Seoul, Republic of Korea. Ahn is rated as a Distinguished expert by MediFind in the treatment of Acquired Agranulocytosis. They are also highly rated in 9 other conditions, according to our data. Their top areas of expertise are Acquired Agranulocytosis, Febrile Neutropenia, Agranulocytosis, and Acute Kidney Failure.

View Profile
View All Doctors
What are the latest Acquired Agranulocytosis Clinical Trials?
A Pilot Study of Granulocyte Colony-Stimulating Factor Starting at 24 Hours vs 72 Hours in Pediatric Oncology Patients
Who is this study for: Pediatric patients with cancer
Status: Recruiting
Start Date: February 1, 2019
Intervention Type: Drug
Study Drugs: Sargramostim
Phase: Phase 4
View Trial
Summary: Chemotherapy places patients at an increased risk of infection. A medication called granulocyte colony-stimulating factor is given as a daily injection in order to help decrease the risk of infection. The purpose of this study is to determine the best time to begin granulocyte colony-stimulating factor while maintaining the same clinical benefits. The current study aims to fill these research gaps...
Match to trials
Find the right clinical trials for you in under a minute
Get started
Predictive Value of ProCalcitonin for the Detection of Bacteraemia in Patients Presenting to the Emergency Department for Low Risk Chemo-induced Febrile Neutropenia According to the MASCC Score: a Prospective, Monocentric Observational Study (CALIF)
Status: Recruiting
Start Date: October 4, 2017
Intervention Type: Diagnostic Test
Phase: Not Applicable
View Trial
Summary: CALIF study is a monocentric observational study which aim is to analyse the value of adding procalcitonin (PCT, a pre-hormon increased in bacterial infection and septicaemia) in the management of chemo-induced febrile neutropenia occurring in patient with solid tumour. Febrile neutropenia will be managed according to international guidelines. PCT will be dosed at initial presentation. Primary obj...
View All Clinical Trials
What are the Latest Advances for Acquired Agranulocytosis?
Phase II feasibility study of adjuvant chemotherapy with docetaxel/cisplatin/S-1 followed by S-1 for stage III gastric cancer.
Condition: Stage III Gastric Cancer
Journal: BMC cancer
Treatment Used: Adjuvant Chemotherapy with Docetaxel/Cisplatin/S-1 Followed by S-1 (DCS)
Number of Patients: 30
Published: October 02, 2021
View publication
Summary: Phase II feasibility study of adjuvant chemotherapy with docetaxel/cisplatin/S-1 followed by S-1 for stage III gastric cancer.
PAC1 Receptor Mediates Electroacupuncture-Induced Neuro and Immune Protection During Cisplatin Chemotherapy.
Condition: Advanced Neurotoxicity or Neuropathies During Chemotherapy
Journal: Frontiers in immunology
Treatment Used: PAC1-Agonists/Electroacupuncture (EA)
Number of Patients: NULL
Published: September 23, 2021
View publication
Summary: PAC1 Receptor Mediates Electroacupuncture-Induced Neuro and Immune Protection During Cisplatin Chemotherapy.
Tired of the same old research?
Check Latest Advances
Comparing the efficacy and side-effects of PDLASTA® (Pegfilgrastim) with PDGRASTIM® (Filgrastim) in breast cancer patients: a non-inferiority randomized clinical trial.
Condition: Breast Cancer
Journal: BMC cancer
Treatment Used: PDLASTA® (Pegfilgrastim) vs. PDGRASTIM® (Filgrastim)
Number of Patients: 80
Published: April 24, 2021
View publication
Summary: Comparing the efficacy and side-effects of PDLASTA® (Pegfilgrastim) with PDGRASTIM® (Filgrastim) in breast cancer patients: a non-inferiority randomized clinical trial.
View All Latest Advances